<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-924" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Alpha-1 Receptor Agonists</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dean II</surname>
            <given-names>James S.</given-names>
          </name>
          <aff>The University of Tennessee HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reddivari</surname>
            <given-names>Anil Kumar Reddy</given-names>
          </name>
          <aff>University of Illinois</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>James Dean II declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anil Kumar Reddy Reddivari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-924.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Alpha-1 agonists are a class of medications used in the management of many disorders, including vasodilatory shock, hypotension, hypoperfusion, septic shock, cardiopulmonary arrest, heart failure decompensation, as well as other lower acuity conditions. This activity reviews the indications, mechanism of action, and contraindications for alpha-1 agonists. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management of patients in need of alpha-1 agonistic effects.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of selected alpha-1 adrenergic agonists.</p></list-item><list-item><p>Describe the adverse effects of selected alpha-1 adrenergic agonists.</p></list-item><list-item><p>Outline the appropriate monitoring of selected alpha-1 adrenergic agonists.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance the effective use of alpha-1 adrenergic agonists and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=924&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=924">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-924.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Alpha-1 adrenergic receptors are present on vascular smooth muscle and myocardial tissue; therefore, stimulation causes vasoconstriction and positive inotropic effects, respectively. Higher acuity indications for alpha-1 receptor agonists include cases of vasodilatory shock, hypotension, and hypoperfusion. Often patients receiving an alpha-1 agonist are concurrently undergoing fluid resuscitation, for example, sepsis or&#x000a0;septic shock, cardiopulmonary arrest, and heart failure decompensation.<xref ref-type="bibr" rid="article-924.r1">[1]</xref>&#x000a0;Other lower acuity indications for alpha-1 agonists would include glaucoma (to lower intraocular pressure) and the use of nasal decongestants. Nasal decongestive effects occur by the induction of local vasoconstrictive effects in the respiratory microvasculature, which leads to a decrease in edema and airflow resistance.<xref ref-type="bibr" rid="article-924.r2">[2]</xref>&#x000a0;The ability to&#x000a0;decrease intraocular pressure primarily takes place by&#x000a0;lowering&#x000a0;aqueous production along with a slight effect from inducing vasoconstriction in the conjunctiva. It is worth noting that the alpha agonist often used for this indication, apraclonidine, lowers aqueous production through concurrent alpha-2 effects&#x000a0;while&#x000a0;vasoconstriction occurs through alpha-1 effects.<xref ref-type="bibr" rid="article-924.r3">[3]</xref></p>
        <p>FDA approved indications for selected alpha-1 agonists (off-label uses indicated when applicable):</p>
        <p>
<bold>Apraclonidine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications: Elevated intraocular pressure and as a diagnostic tool for Horner syndrome</p>
          </list-item>
          <list-item>
            <p>Administration: Eye drops</p>
          </list-item>
          <list-item>
            <p>Notes: Apraclonidine is also called iopidine. Often the elevated intraocular pressure that necessitates its use is caused by glaucoma. This drug is primarily an alpha-2 adrenergic agonist but does also&#x000a0;produce&#x000a0;alpha-1 agonist effects.</p>
          </list-item>
        </list>
        <p>
<bold>Epinephrine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications: Mucosal congestion, glaucoma, asthma, and emergency treatment of severe hypersensitivity reactions. Epinephrine is also the primary drug used to aid the reversal of cardiac arrest during cardiopulmonary resuscitation (CPR).</p>
          </list-item>
          <list-item>
            <p>Administration: Intravenous, inhalation, nebulization, intramuscular injection, and subcutaneous injection</p>
          </list-item>
          <list-item>
            <p>Notes: Epinephrine is a hormone and a neurotransmitter, also known as adrenaline, that is secreted endogenously by the adrenal medulla as part of the sympathetic response. It is also used in lidocaine drug formulations to prolong the local anesthetic effects of lidocaine and provide local hemostasis.<xref ref-type="bibr" rid="article-924.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Methoxamine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications: Hypotension (especially due to spinal anesthesia), hemorrhage, adverse medication reaction, and shock caused by surgery, brain damage, or trauma</p>
          </list-item>
          <list-item>
            <p>Administration: Injection and intravenous</p>
          </list-item>
          <list-item>
            <p>Notes: Methoxamine causes prolonged peripheral vasoconstriction but has little to no effect on the central nervous system. Unlike many alpha-1 agonists that have mixed alpha-1 or alpha-2 activity and beta action, methoxamine is a selective alpha-1 agonist.</p>
          </list-item>
          <list-item>
            <p>Discontinued in the USA</p>
          </list-item>
        </list>
        <p>
<bold>Norepinephrine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications: Vasodilatory shock (i.e., septic shock and neurogenic shock), acute hypotension (used as a vasopressor), and cardiac arrest (used as an adjunct therapy)</p>
          </list-item>
          <list-item>
            <p>Administration: Intravenous drip and injection</p>
          </list-item>
          <list-item>
            <p>Notes: The neurotransmitter, norepinephrine, is the precursor to epinephrine and is also secreted by the adrenal medulla.&#x000a0;Norepinephrine and epinephrine are known as catecholamines.</p>
          </list-item>
        </list>
        <p>
<bold>Oxymetazoline</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications: Nasal congestion, facial erythema due to rosacea, and ophthalmic allergic reactions</p>
          </list-item>
          <list-item>
            <p>Administration: Topical cream, nasal spray, eye drops</p>
          </list-item>
        </list>
        <p>
<bold>Phenylephrine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications: Anesthesia-associated and shock-associated hypotension,&#x000a0;conditions or&#x000a0;procedures necessitating dilation of the pupil, and nasal congestion (provides local vasoconstrictive effects)</p>
          </list-item>
          <list-item>
            <p>Administration: Oral, intravenous, and topical (eye drops and rectal ointment)</p>
          </list-item>
          <list-item>
            <p>Notes: Phenylephrine is used off-label as a first-line treatment for ischemic priapism.</p>
          </list-item>
        </list>
        <p>
<bold>Pseudoephedrine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications: Nasal congestion, rhinitis, otitis media, sinusitis, and tracheobronchitis</p>
          </list-item>
          <list-item>
            <p>Administration: Oral tablet or syrup</p>
          </list-item>
          <list-item>
            <p>Notes: Medications containing pseudoephedrine are often offered as a combined product with ibuprofen and/or an antihistamine, It causes the release of neuronal norepinephrine</p>
          </list-item>
        </list>
        <p>
<bold>Tetryzoline</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications: Minor&#x000a0;eye&#x000a0;irritation (provides short-term relief) or inflammation</p>
          </list-item>
          <list-item>
            <p>Administration: Eye drops</p>
          </list-item>
        </list>
        <p>
<bold>Xylometazoline</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications: Nasal congestion and minor nasal inflammation</p>
          </list-item>
          <list-item>
            <p>Administration: Nasal spray or drops</p>
          </list-item>
          <list-item>
            <p>Notes: This agent decreases congestion through vasoconstriction effects</p>
          </list-item>
        </list>
        <p>It is worth noting that many&#x000a0;agents that are &#x0201c;alpha-1 agonists&#x0201d;&#x000a0;have at least some mixed alpha-1 and alpha-2 activity, and&#x000a0;others have mixed alpha and beta-agonistic activity.</p>
      </sec>
      <sec id="article-924.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Adrenergic receptors are G-protein-coupled receptors (GPCR) that play a central role in the sympathetic nervous system. The alpha-1 adrenergic receptors respond to norepinephrine and epinephrine and act through the Gq signaling pathway to facilitate several effects, some specific to the alpha-1 receptor and other effects shared with alpha-2 receptors.<xref ref-type="bibr" rid="article-924.r5">[5]</xref>&#x000a0;When the alpha-1 receptor is activated, the Gq signaling pathway kicks off. This activation leads to phospholipase C activation, and the second messengers, inositol triphosphate (IP3) and diacylglycerol (DAG) cause smooth muscle contraction and glycogenolysis by increasing intracellular calcium.<xref ref-type="bibr" rid="article-924.r6">[6]</xref>&#x000a0;Many of the desired effects of alpha-1 agonists&#x000a0;are a result&#x000a0;of the vascular smooth muscle contraction resulting in increased systemic vascular resistance, thereby&#x000a0;increasing afterload on the heart, which in turn increases blood pressure and decreases cardiac output.<xref ref-type="bibr" rid="article-924.r4">[4]</xref></p>
      </sec>
      <sec id="article-924.s4" sec-type="Administration">
        <title>Administration</title>
        <p>In&#x000a0;conditions involving the eyes (such as elevated intraocular pressure, irritation of the eye, or procedures requiring dilation of the pupil), an alpha-1 agonist will&#x000a0;most often be administered topically via eye drops. Medications for nasal congestion are often a combination of multiple&#x000a0;active agents, and the route of administration will vary from oral tablets or capsules, oral liquid&#x000a0;in pediatric patients, nasal sprays for local effect, as seen with oxymetazoline. Epinephrine is given intravenously during CPR and via intramuscular injection during anaphylactic shock.</p>
      </sec>
      <sec id="article-924.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>In general, alpha agonists can cause decreased renal perfusion, increased cardiac afterload, and decreased venous compliance. Phenylephrine, specifically, has documented cases of renal failure. Researchers have also conducted several studies&#x000a0;indicating that alpha-1 agonists cause&#x000a0;adverse effects on gastrointestinal blood flow due to their inherent vasoconstriction.<xref ref-type="bibr" rid="article-924.r4">[4]</xref> Epinephrine, while used as an adjunctive&#x000a0;to lidocaine injections for local anesthetic effect, has been&#x000a0;shown to cause a clinically significant increase in pain when compared to placebo injections.<xref ref-type="bibr" rid="article-924.r7">[7]</xref></p>
      </sec>
      <sec id="article-924.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The suggested general&#x000a0;guideline is that each patient&#x02019;s situation is taken into account when considering the use of alpha-1 agonists. The indications described above often have specific benefits outweighing the potential risks. Still, in general, an alternative vasopressor should be used when possible to avoid adverse effects such as increased cardiac afterload. Catecholamines (norepinephrine and epinephrine) are contraindicated for the treatment of hypotension in the setting of increased serotonin as they can exacerbate the release of serotonin that is already occurring in the underlying disease state. In patients with carcinoid tumors, it is advisable for phenylephrine, octreotide, antihistamines, and hydrocortisone to merit consideration for use instead of a catecholamine.<xref ref-type="bibr" rid="article-924.r4">[4]</xref></p>
      </sec>
      <sec id="article-924.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The monitoring of alpha-1 agonists will depend on the patient&#x02019;s situation and the drug involved. Patients who are experiencing an anaphylactic reaction will need treatment with epinephrine. Following the cessation of anaphylactic symptoms, the patient&#x000a0;must remain under observation for the next six to twelve hours. Current data indicates that 6 hours of observation excludes the occurrence of a secondary reaction in 95% of patients, so&#x000a0;the standard of care guidelines&#x000a0;require a minimum of 6 hours of observation.<xref ref-type="bibr" rid="article-924.r8">[8]</xref>&#x000a0;Patients who&#x000a0;adhere to the dosage recommendations while taking pseudoephedrine, xylometazoline, or oxymetazoline for an upper respiratory infection do not typically require monitoring as long as symptoms improve as expected.</p>
      </sec>
      <sec id="article-924.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The toxicity of alpha-1 agonists differs between the individual compounds, but specific adverse effects are consistent across the class. Phenylephrine, a prototypical agent, has been used in studies to represent alpha-1 agonistic actions due to its alpha-1 receptor selectivity. Toxicity related to phenylephrine presents as reflex bradycardia, headache, tingling extremities, hypertension, cardiac arrhythmias, and a feeling of fullness in the head. Treatment for an overdose with alpha-1 agonists is mostly supportive, although the application of vasodilators, along with a chronotropic agent, may be beneficial in certain instances. There is no specific&#x000a0;antidote for toxicity related to this class of medications.<xref ref-type="bibr" rid="article-924.r9">[9]</xref><xref ref-type="bibr" rid="article-924.r10">[10]</xref></p>
      </sec>
      <sec id="article-924.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Alpha-1 agonists have a diverse range of uses, settings, and acuities. Communication between the various members of the interprofessional healthcare team is crucial to ensuring that the patients&#x000a0;receive the appropriate dose following an effective timeline. These agents modify vascular smooth muscle contraction and also have powerful&#x000a0;positive inotropic effects. Patient-centered care will entail the healthcare provider&#x000a0;discerning when a systemic alpha-1 agonist is genuinely a necessity or when an alternative vasopressor could be implemented to avoid the risk of adverse effects. Communication between nurses, pharmacists, and physicians will&#x000a0;improve&#x000a0;the care for the patients needing alpha-1 agonists and prevent comorbidities. For example, patients with congestive heart failure or chronic renal failure require detailed attention due to their propensity to experience an increase in afterload&#x000a0;and renal vasoconstriction more acutely. The pharmacist can ensure dosing and administration is appropriate for the patient/case, and nurses can perform follow-up to check for therapeutic effectiveness and adverse drug reactions.&#x000a0;</p>
        <p>During a cardiopulmonary resuscitation (CPR) attempt, there is often a nurse assigned to record the dose and time of&#x000a0;each medication administered. One of the main objects of this team member is to call out each time a patient receives a dose of epinephrine, record the time, and then alert the team when it is time for the next dose, should it be required.<xref ref-type="bibr" rid="article-924.r11">[11]</xref>&#x000a0;This communication between the nursing staff administering medications, the physician guiding the resuscitation attempt, and the nurse assigned to record is an example of the clear and coordinated interprofessional care that alpha-1 agonists often require. Proper utilization of these agents requires the dedicated attention of nurses, clinicians, and pharmacists, working as a cohesive interprofessional team, who are well acquainted with the patient's condition and the medications administered. [Level 5]</p>
      </sec>
      <sec id="article-924.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=924&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=924">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/924/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=924">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-924.s11">
        <title>References</title>
        <ref id="article-924.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacha</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lat</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Vasoactive Agent Use in Septic Shock: Beyond First-Line Recommendations.</article-title>
            <source>Pharmacotherapy</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>369</fpage>
            <page-range>369-381</page-range>
            <pub-id pub-id-type="pmid">30644586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-924.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soleimani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Akbarpour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of phenylephrine nasal drops in bronchiolitis.</article-title>
            <source>Iran J Pediatr</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>593</fpage>
            <page-range>593-7</page-range>
            <pub-id pub-id-type="pmid">25793067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-924.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morales</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Abdul-Rahim</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Crosson</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Ocular effects of apraclonidine in Horner syndrome.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>118</volume>
            <issue>7</issue>
            <fpage>951</fpage>
            <page-range>951-4</page-range>
            <pub-id pub-id-type="pmid">10900109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-924.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thiele</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Nemergut</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The clinical implications of isolated alpha(1) adrenergic stimulation.</article-title>
            <source>Anesth Analg</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>113</volume>
            <issue>2</issue>
            <fpage>297</fpage>
            <page-range>297-304</page-range>
            <pub-id pub-id-type="pmid">21519053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-924.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piascik</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Alpha1-adrenergic receptors: new insights and directions.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>298</volume>
            <issue>2</issue>
            <fpage>403</fpage>
            <page-range>403-10</page-range>
            <pub-id pub-id-type="pmid">11454900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-924.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Minneman</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Recent progress in alpha1-adrenergic receptor research.</article-title>
            <source>Acta Pharmacol Sin</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>11</issue>
            <fpage>1281</fpage>
            <page-range>1281-7</page-range>
            <pub-id pub-id-type="pmid">16225747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-924.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Nah</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>A Prospective, Comparative Study of the Pain of Local Anesthesia Using 2% Lidocaine, 2% Lidocaine With Epinephrine, and 2% Lidocaine With Epinephrine-Bupivicaine Mixture for Eyelid Surgery.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2017</year>
            <season>Mar/Apr</season>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>132</fpage>
            <page-range>132-135</page-range>
            <pub-id pub-id-type="pmid">26974418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-924.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Duration of Observation for Detecting a Biphasic Reaction in Anaphylaxis: A Meta-Analysis.</article-title>
            <source>Int Arch Allergy Immunol</source>
            <year>2019</year>
            <volume>179</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-36</page-range>
            <pub-id pub-id-type="pmid">30763927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-924.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Benna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Boyle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Holley</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Extravasation injuries in adults.</article-title>
            <source>ISRN Dermatol</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>856541</fpage>
            <pub-id pub-id-type="pmid">23738141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-924.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Richards</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Maani</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <chapter-title>Phenylephrine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30521222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-924.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gough</surname>
                <given-names>CJR</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>The role of adrenaline in cardiopulmonary resuscitation.</article-title>
            <source>Crit Care</source>
            <year>2018</year>
            <month>May</month>
            <day>29</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <pub-id pub-id-type="pmid">29843791</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
